<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03396107</url>
  </required_header>
  <id_info>
    <org_study_id>ACESC</org_study_id>
    <nct_id>NCT03396107</nct_id>
  </id_info>
  <brief_title>Antenatal Corticosteroid in Elective Cesarean Section</brief_title>
  <official_title>Role of Antenatal Corticosteroid Use in Elective Term Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Caesarean section is a risk factor for the development of neonatal respiratory complications,&#xD;
      mostly respiratory distress syndrome (RDS) and transient tachypnoea of the new-born, both in&#xD;
      term and preterm infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infants born at term by caesarean delivery are more likely to develop respiratory morbidity&#xD;
      than infants born vaginally, and this risk increases furthermore for the subgroup of children&#xD;
      born by elective caesarean section, i.e. before onset of labour, with potentially severe&#xD;
      implications. The risk is decreasing with advancing gestational age, and infants born between&#xD;
      37+0 and 37+6 weeks are at 1.7 times more risk for respiratory complications than those born&#xD;
      between 38+0 and 38+6 weeks, which in turn are at 2.4 times more risk than the infants born&#xD;
      between 39+0 and 39+6 weeks. If women were given two intramuscular injections of 12 mg of&#xD;
      dexamethasone, two doses for 48 hrs,the rates of admissions were 5.2% at 37 weeks, 2.8% at 38&#xD;
      weeks, and 0.6% at 39 weeks. Although none of the babies in the control group died, admission&#xD;
      will increase parental anxiety, the cost to nursery unit and invasive procedures including&#xD;
      artificial ventilation giving mothers dexamethasone, two doses before elective section halved&#xD;
      neonatal morbidity. Five studies lasting between three and 20 years with more than 1500&#xD;
      patients have shown no adverse effect of single course of antenatal corticosteroid, neither&#xD;
      through infection of the fetus or mother nor in long term neurological or cognitive effect In&#xD;
      view of this evidence, it is currently recommended that elective caesarean section should be&#xD;
      deferred to 39 weeks. However approximately 10%-15% of woman planed for c/s may deliver&#xD;
      before 38 weeks, and there may be concern on waiting in the presence of speci c indications&#xD;
      or previous history. Respiratory morbidity in cases of term elective caesarean birth appears&#xD;
      to have a different pathophysiology than in preterm birth, and retention in the lungs being&#xD;
      the most likely cause.&#xD;
&#xD;
      Interestingly, recent evidence indicates that apart from the traditional mechanical concept&#xD;
      of vaginal squeeze, molecular mechanisms (predominantly lung epithelial sodium channels&#xD;
      promote alveolar uid drainage, and these channels are under active in fetuses unexposed to&#xD;
      the process of labor. Glucocorticoid appears to increase the number and the function of&#xD;
      thyroid hormones, providing a rational for their exogenous administration in cases of&#xD;
      elective caesarean delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">May 24, 2020</completion_date>
  <primary_completion_date type="Actual">November 25, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of respiratory complications after cesarean section</measure>
    <time_frame>30 min</time_frame>
    <description>To determine respiratory distress in infants born by elective cesarean section</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">498</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 6mg, IM, 48 hours before cesarean section</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 6mg, IM, 48 hours before cesarean section</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 6mg, IM, 48 hours before cesarean section</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 6mg, IM, 48 hours before cesarean section</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Maternal age (18-35 years)&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Gestational age (38-40 years)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major maternal morbidities as DM and pre-eclampsia&#xD;
&#xD;
          -  Sever oligohydramnios&#xD;
&#xD;
          -  Premature rupture of membranes&#xD;
&#xD;
          -  Women who receive steroids during pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Fayek, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Barber EL, Lundsberg LS, Belanger K, Pettker CM, Funai EF, Illuzzi JL. Indications contributing to the increasing cesarean delivery rate. Obstet Gynecol. 2011 Jul;118(1):29-38. doi: 10.1097/AOG.0b013e31821e5f65.</citation>
    <PMID>21646928</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Mostafa Haroun</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

